Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro‐drug of miridesap
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14956
Abstract: Miridesap, a depleter of serum amyloid P component (SAP), forms an essential component of a novel approach to remove systemic amyloid deposits; low oral bioavailability necessitates that it is given parenterally. We sought to identify… read more here.
Keywords: preclinical profile; pro drug; profile clinical; miridesap ... See more keywords